Authors
Latest:
Mechanism of VB-111 in Treating Ovarian Cancer: Bradley Monk, MD, FACOG, FACSBradley Monk, MD, FACOG, FACS, discusses the mechanism of VB-111 in patients with ovarian cancer.
Latest:
The Power and Potential of Natural Killer Cell Therapies: A New AwakeningNatural killer cells could redefine medicine and offer new hope for cancer, autoimmune diseases, and neurological disorders through advanced CAR-NK therapies.
Latest:
Peter Marks, MD, PhD, on Bringing More Gene Therapies to PatientsThe director of the Center for Biologics Evaluation and Research at the FDA discussed his keynote speech at the 2023 MDA Conference.
Latest:
Cory R. Nicholas, PhD, on Future Plans for Additional Research With Epilepsy Cell Therapy NRTX-1001The cofounder and CEO of Neurona Therapeutics discussed the company’s goals to evaluate the cell therapy in more types of epilepsy and potentially even in Alzheimer disease.
Latest:
Françoise Bernaudin, MD, on alloSCT Superiority Over SOC for Sickle Cell AnemiaThe head of the Referral Center for Sickle Cell Disease and Clinical Research Department at Hôpital Intercommunal de Créteil of the Université Paris Cité discussed the Drepagreffe-1 and 2 studies and improvements seen over 10 years of follow-up.
Latest:
Massimo Trucco, MD, on the Potential of Islet Cell TransplantThe director of the Alleghany Health Network Institute of Cellular Therapeutics discussed possible applications of the procedure.
Latest:
Omid Hamid, MD, on Assessing TIL Combination Therapies, Expanding Past MelanomaThe professor from Cedars Sinai discussed further research being conducted in the field after lifileucel’s approval.
Latest:
Encapsulated Cell Therapy for Retinal DiseasesJohn Pollack, MD, discusses gene therapy advancements for retinal diseases.
Latest:
Shebli Atrash, MD, on BCMA-Directed Therapy Options for Multiple MyelomaShebli Atrash, MD, discussed the current landscape of available BCMA-directed therapies for treating multiple myeloma.
Latest:
Evaluating Epigenetic Gene Therapy for the Treatment of FSHDAlexandra Collin de l’Hortet, PhD, the head of therapeutics at Epic Bio, discussed EPI-321, an investigational treatment for facioscapulohumeral muscular dystrophy.
Latest:
CARTITUDE Trials in Multiple MyelomaExperts discussed safety and efficacy data of cilta-cel for R/R MM from the CARTITUDE-1 and CARTITUDE-2 studies.
Latest:
Future Research in Gene and Cell Therapy ConditioningKevin Heller, MD, executive vice president of research, Jasper Therapeutics, discussed future research with JSP191.
Latest:
Advantages of Concurrently Investigating Gene Therapies in Dogs and HumansDan Oliver, cofounder and chief executive officer, Rejuvenate Bio, discussed the advantages of developing gene therapies for both dogs and humans.
Latest:
Sid Kerkar, MD, on Developing CAR T Therapies Without Lymphodepletion ChemotherapyThe vice president of oncology and research and development at Exuma Biotech discussed the company’s platforms, including CAR-TaNK cells.
Latest:
Matthew Frigault, MD, MS, on CART-ddBCMA's Potential in Multiple MyelomaThe study's primary investigator shared his thoughts on where CART-ddBCMA could fit within the treatment landscape.
Latest:
Axi-Cel vs Tisa-Cel in R/R Diffuse Large B-Cell Lymphoma : Guenther Koehne, MD, PhDThe deputy director and chief of stem cell transplantation at Miami Cancer Institute discussed the study of axicabtagene ciloleucel vs tisagenlecleucel in relapsed or refractory diffuse large B-cell lymphoma.
Latest:
Jonathan Yen, PhD, on Continuing Research With Prime Editing for Sickle Cell DiseaseThe director of therapeutic genome engineering, St. Jude Children’s Research Hospital discussed challenges with performing prime editing in cells.
Latest:
Multiple Myeloma KarMMA Trial Methodology: Larry Anderson, MDThe associate professor from Harold C. Simmons Comprehensive Cancer Center discussed the methodology of the phase 2 KarMMa trial.
Latest:
Bringing Gene Therapies to Market With the Help of MEAsWith a new paradigm of treating previously incurable diseases comes a new pay paradigm for million-dollar therapies.
Latest:
Developing a Safer Allogeneic Cell Therapy for Ovarian CancerMichael Heffernan, chairman and chief executive officer, Avenge Bio, discussed AVB-001's lower systemic toxicity profile seen in preclinical studies.
Latest:
The Importance of Precise Reproducibility of AAVsScott Jeffers, PhD, the chief technology officer at GenSight Biologics, discussed using Verdot’s FlexiPro system to produce Lumevoq gene therapy.
Latest:
Ben Creelan, MD, on the Potential of Logic-gated Tmod CAR-T in Lung Cancer and Other Solid TumorsThe medical oncologist at Moffitt Cancer Center spoke about A2 Bio’s A2B530 as part of a larger discussion of novel cell therapy approaches in solid tumors.
Latest:
Evan Zynda, PhD, on Optimizing Manufacturing to Increase Access to Cell TherapyThe senior scientist at Thermo Fisher Scientific discussed the company’s approach to scaling and strategic partnerships.
Latest:
Claire Roddie PhD, FRCPath, MBChB, MRCP, on the Potential Advantage Obe-cel's Fast Off-rate CD19 Binding DomainThe associate professor at University College London also discussed unmet needs that remain in r/r B-ALL and another presentation of interest at ASCO’s 2023 conference.
Latest:
Rajni Agarwal-Hashmi, MD, on Safety Advantages of Gene Therapy in Fanconi Anemia Over SOCThe professor of pediatrics at Stanford Cancer Institute discussed recent data from clinical trials of the lentiviral gene therapy RP-L102.
Latest:
CAR T and Other Emerging Therapies in R/R Multiple Myeloma: Kenneth H. Shain, MD, PhDThe hematologist/oncologist at Moffitt Cancer Center discussed emerging therapies for patients with relapsed/refractory multiple myeloma.
Latest:
Paula Rodríguez Otero, MD, PhD, on Demonstrating Ide-cel's PFS Superiority in Triple-Class-Exposed R/R Multiple MyelomaThe hematologist at the University of Navarra discussed updated data from the phase KarMMa-3 trial.
Latest:
J. Andrew Livingston, MD, on Starting the Shift Toward Targeted Therapies in SarcomaThe associate professor at MD Anderson Cancer Center discussed his future outlook and goals for the field of sarcoma.
Latest:
Dan Shelly, PhD, on Developing an Allogeneic, Adaptable CAR PlatformThe vice president of business development and alliances at Prescient Therapeutics discussed advantages of the OmniCAR, SpyTag, and SpyCatcher technologies.
Latest:
The Power and Potential of Natural Killer Cell Therapies: A New AwakeningNatural killer cells could redefine medicine and offer new hope for cancer, autoimmune diseases, and neurological disorders through advanced CAR-NK therapies.
